Oncology Nurse Edition Publications Info

Oncologists Reflect on Pandemic's Lasting Impact on Cancer Care

Phase 2 data support further investigation of trastuzumab rezetecan as a treatment for patients with HER2-mutant non–small cell lung cancer.

Aditya Bardia, MD, MPH;Ritu Salani, MD;Scarlett Lin Gomez, PhD;Marwan G. Fakih, MD;Elizabeth Ren Zhang-Velten, MD, PhD;Frances Chow, MD;James B. Yu, MD, MHS, FASTRO

Active Monitoring May Be Safe Vs Surgery in Certain Low-Risk DCIS Populations

Hear from leading cancer experts about the lasting impact the COVID-19 pandemic has left on clinical practice.

Findings from the COMET trial support the potential safety and acceptability of active monitoring among patients with ductal carcinoma in situ.

Traversing the Complexities of Non-Clear Cell Renal Cell Carcinoma

Findings from the COMET trial support the potential safety and acceptability of active monitoring among patients with ductal carcinoma in situ.

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD;Stephanie A. Berg, DO

March 7th 2025

3 Things You Should Know About Treating Epithelioid Sarcoma

A brief overview of the current RCC landscape was provided in the most recent Oncology Decoded podcast.

ONCOLOGY Staff

AI-Assisted Mammography Screenings Show Preliminary Detection Improvement

Epithelioid sarcoma is individualized based on disease characteristics, it's methods of treatment vary, and systemic treatment is both targeted medication and chemotherapy.

The assistance of AI-based computer-aided detection for mammogram screenings did not impact recall rates in a radiologist’s standard single reading.

Roman Fabbricatore

March 9th 2025

Novel ADC Elicits Meaningful Activity in Pretreated HER2-Mutant NSCLC

The assistance of AI-based computer-aided detection for mammogram screenings did not impact recall rates in a radiologist’s standard single reading.

Related Content

Oncologists Reflect on Pandemic's Lasting Impact on Cancer Care

Phase 2 data support further investigation of trastuzumab rezetecan as a treatment for patients with HER2-mutant non–small cell lung cancer.

Aditya Bardia, MD, MPH;Ritu Salani, MD;Scarlett Lin Gomez, PhD;Marwan G. Fakih, MD;Elizabeth Ren Zhang-Velten, MD, PhD;Frances Chow, MD;James B. Yu, MD, MHS, FASTRO

Active Monitoring May Be Safe Vs Surgery in Certain Low-Risk DCIS Populations

Hear from leading cancer experts about the lasting impact the COVID-19 pandemic has left on clinical practice.

Traversing the Complexities of Non-Clear Cell Renal Cell Carcinoma

Findings from the COMET trial support the potential safety and acceptability of active monitoring among patients with ductal carcinoma in situ.

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD;Stephanie A. Berg, DO

March 7th 2025

3 Things You Should Know About Treating Epithelioid Sarcoma

A brief overview of the current RCC landscape was provided in the most recent Oncology Decoded podcast.

ONCOLOGY Staff

AI-Assisted Mammography Screenings Show Preliminary Detection Improvement

Epithelioid sarcoma is individualized based on disease characteristics, it's methods of treatment vary, and systemic treatment is both targeted medication and chemotherapy.

Roman Fabbricatore

March 9th 2025